Overview

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Status:
Not yet recruiting

Trial end date:
2025-02-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have BRCA1/2 mutations .

Phase:

Phase 4

Details

Lead Sponsor:

AstraZeneca

Collaborators:

Foundation Medicine, Inc.
Merck Sharp & Dohme LLC
Myriad Genetics, Inc.

Treatments:

Abiraterone Acetate
Olaparib
Prednisone